APVO News and Press, Aptevo Therapeutics Inc. From 12/06/19

SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to APVO...

Preclinical Data Show That ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti-tumor Activity and Induces an Immunological Memory Response SEATTLE and LUND, Sweden, Nov. 08, 2019 (GLOBE NEWSWIRE) -- ...

Aptevo Therapeutics (NASDAQ: APVO ): Q3 GAAP EPS of -$0.23 beats by $0.01 . More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

Reports Record Net Revenue for IXINITY;  Achieves 55% Increase in Year-over-Year Quarterly Net Revenue Advances APVO436 Phase 1/1b Clinical Study in AML/MDS SEATTLE, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on...

Several days ago, Aptevo Therapeutics ( APVO ) provided a corporate and pipeline update that surprised me (and I don't get surprised easily). To begin with, the company's hemophilia B drug IXINITY will do about $9M in revenue for Q3'19. This is a very important milestone for the company,...

Reports Record Quarterly IXINITY ® Net Revenue and New Patient Conversions  Following Launch of New 3,000 IU Assay Provides Update on Ongoing APVO436 Phase 1/1b Clinical Study; Evidence of Potential Clinical Activity Emerging; No Dose-Limiting Toxicities or Anti-drug An...

New ADAPTIR Candidate APVO603 is a Dual-Agonistic Bispecific Antibody Targeting 4-1BB and OX40 APVO603 is Designed to Induce Synergistic Effects on Immune Responses with Potential to Enhance Anti-Tumor Immune Response Against Solid Tumors SEATTLE, Sept. 19, 2019 (GLOBE NEWSWIRE)...

As I said in the previous article on the company, my metric for Aptevo Therapeutics ( APVO ) having a good Q2'19 quarter was even a slight increase in IXINITY revenue (the company's commercial Hemophilia B drug). The company reported IXINITY revenue of $7.4 million, which was up by $0.4M s...

Aptevo Therapeutics (NASDAQ: APVO ): Q2 GAAP EPS of -$0.30 misses by $0.04 . More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

Reports Positive Preliminary Top-Line Safety Data for APVO210 Phase 1 Single Ascending Dose (SAD) Clinical Study Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD) Study Commences Dosing in Cohort 4 of APVO436 Phase 1 AML/MDS Clinical Trial Achieves 32% Increase in ...